2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1635

Validity of Patient-Reported Outcomes Measurement Information System Measures in Ankylosing Spondylitis Patients
Abstract Number: 1636

Frequency and Specificity of MRI Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis and Non-Specific Back Pain: First Analysis of MRI Scans from the Assessments in Spondyloarthritis International Society Classification Cohort
Abstract Number: 1637

Serious Infections Among Psoriatic Arthritis Patients Taking TNF Inhibitors Versus Non-TNF Biologics: A Systematic Review and Network Meta-Analysis
Abstract Number: 1638

Impact of Extra-Articular Manifestations on Patient-Reported Outcomes in Ankylosing Spondylitis and Psoriatic Arthritis: Interim Results from the Complete Studies
Abstract Number: 1639

Uveitis As First Symptom in Patients with Spondyloarthritis. Data from the Spanish Registry Regisponser
Abstract Number: 1640

Work Disability in Psoriatic Arthritis Patients
Abstract Number: 1641

Spa-Net: A Disease-Specific Integrated Ehealth System and Quality Registry for Spondyloarthritis in Daily Practice in the Netherlands
Abstract Number: 1642

Systematic Screening of Comorbidities Improves Vaccination Rates, Skin Cancer Screening and Vitamin D Supplementation in Patients with Axial Spondyloarthritis: Results of a Prospective, Controlled ,One Year Randomised Trial
Abstract Number: 1643

Psa Impact of Disease Questionnaire Scores Are Correlated with Disease Activity, As Measured By Cdapsa in Patients with Psa
Abstract Number: 1644

Improvement in Morning Stiffness in Subjects with Psa Is Associated with Improvements in Pain, Physical Function, and Patient Global Response to Treatment
Abstract Number: 1645

Clinical Features of Axial Spondyloarthritis Patients Diagnosed in Secondary Versus a Tertiary Hospital
Abstract Number: 1646

Prevalence of Spondyloarthritis in Patients with Anterior Uveitis
Abstract Number: 1647

Uveitis, the Most Faithful Partner of Axial Spondyloarthritis
Abstract Number: 1648

Smoking Status in Patients with Psoriasis and Psoriatic Arthritis: An Irish Perspective
Abstract Number: 1649

Cohort Identification of Axial Spondyloarthritis in a Large Healthcare Dataset: Current and Future Methods

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].